Bafna Pharmaceuticals, a Chennai-based pharma company engaged in the business of manufacturing of pharmaceutical formulations of betalactum and non-betalactum, has received approval from Medicines and Healthcare products Regulatory Agency of the UK (UK MHRA) for manufacturing paracetamol tablets and loperamide capsules .
This is the eighth formulation approval received from UK MHRA for a product by Bafna Pharma for contract manufacturing, a company release said.
Commenting on UK MHRA approval Mahaveer Chand Bafna, chairman and MD of Bafna Pharmaceuticals Ltd. says, "The approval from UK MHRA for paracetamol and loperamide would further help us strengthen our already expanding business in the European market. UK MHRA approval will enable Bafna Pharma to widen the customer base in Europe. Following the recent launch of our FR&D facility in Chennai, we will be filing dossiers for the ever growing UK and the European Markets."
The UK- MHRA has granted Bafna Pharma the approval for manufacturing paracetamol tablets 500mg & paracetamol caplets 500 mg. These tablets are used in the treatment of mild to moderate pain including headache, toothache, period pains, symptomatic relief of influenza, feverish colds and rheumatic aches and pains. The active ingredient, paracetamol is a centrally acting analgesic (a pain killer that acts on pain centres in the brain), which is used to relieve pain in the body.
Similarly, loperamide 2mg capsules is used for the treatment of symptoms of sudden, short-term diarrhoea (acute diarrhoea) in adults and children over 12 years. Loperamide 2mg capsules contain the active ingredient loperamide hydrochloride which belongs to a group of medicines called antidiarrhoeals which is a synthetic opioid that inhibits gut motility by binding to opiate receptors in the gut wall and may also reduce gastrointestinal secretions, resulting in improvement in the diarrhoea symptoms.